Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379702 | 0.84 | GDA (0.34) | PDPK1 | |
| SCHEMBL16147026 | 0.81 | ADORA3 (0.37) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL887124 | 0.80 | CYP1A2 (0.40) | LMNAPOLB | |
| SCHEMBL11876693 | 0.79 | XDH (0.39) | PDPK1CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL16146172 | 0.78 | HTT (0.38) | CDK1LMNAXDHMEN1KMT2A | |
| SCHEMBL9118 | 0.78 | NOS1 (0.38) | PDPK1CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL14110227 | 0.78 | XDH (0.38) | PDPK1CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL16146260 | 0.77 | ESR1 (0.44) | CDK2 | |
| SCHEMBL11334542 | 0.77 | LMNA (0.33) | PDPK1LMNAMEN1POLBKMT2A | |
| Xanthine SCHEMBL918381 | 0.76 | MEN1 (0.34) | LMNAMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20200263231-A1 | Fluorogenic dyes for high sensitivity DNA detection | Life Technologies Corporation | 2020-08-20 | — | — | US | disclosed |
| EP-2473563-B1 | REACTIVE CYANINE COMPOUNDS | PROMEGA CORP (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10139400-B2 | Carboxy X rhodamine analogs | PROMEGA CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2963033-B1 | BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATES, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES | UNIV SHANGHAI JIAOTONG (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| EP-2782916-B1 | CARBOXY X RHODAMINE ANALOGS | PROMEGA CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2408863-B1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | PROMEGA CORP (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2972229-B1 | NEW SILICON AND GERMANIUM DYES FOR USE IN GENETIC IDENTITY | PROMEGA CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2011026085-A2 | REACTIVE CYANINE COMPOUNDS | PROMEGA CORPORATION (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010107816-A2 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | PROMEGA CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100233710-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2010-09-16 | — | — | US | disclosed |
| EP-0740689-B1 | SUBSTITUTED UNSYMMETRICAL CYANINE DYES WITH SELECTED PERMEABILITY | MOLECULAR PROBES INC (US) | 2002-01-30 | — | — | EP | disclosed |
| US-5733539-A | PLANT FERMENTED MATRIX MATERIAL CONTAINIGN AMINO ACID | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1998-03-31 | — | — | US | disclosed |
| US-5719031-A | MEASURING FLUORESCENCE | MOLECULAR PROBES, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0796564-A1 | FEED FOR FISHES AND SHELLFISHES | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1997-09-24 | — | — | EP | disclosed |
| US-5658751-A | SUBSTITUENTS ON PYRIDINIUM OR QUINOLINIUM RING SYSTEM SERVE TO INCREASE OR DECREASE PERMEABILITY, SELECTIVITY AND BINDING AFFINITY OF NUCLEIC ACID STAINS; FORM FLUORESCENT COMPLEXES WITH NUCLEIC ACIDS | MOLECULAR PROBES, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5656449-A | STAINING NUCLEIC ACIDS | MOLECULAR PROBES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996013552-A2 | SUBSTITUTED UNSYMMETRICAL CYANINE DYES WITH SELECTED PERMEABILITY | MOLECULAR PROBES, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885CCNB2 3940/4885CDK1 2235/4885 |
| US-20100233710-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | POLRMT, POLB, POLL | PDPK1 4385/4885CCNB2 1117/4885CDK1 1973/4885 |
| US-10139400-B2 | Carboxy X rhodamine analogs | PRCP, CPA3, CPA4 | PDPK1 4776/4885CCNB2 3391/4885CDK1 3140/4885 |
| US-20200263231-A1 | Fluorogenic dyes for high sensitivity DNA detection | POLRMT, POLM, DNMT3A | PDPK1 3905/4885CCNB2 748/4885CDK1 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.